These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21166508)

  • 1. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C; Ferro M; Di Lorenzo G
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sipuleucel-T (APC8015) for prostate cancer.
    So-Rosillo R; Small EJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy: an emerging strategies against prostate castration resistant cancer].
    Mansi L; Thiery-Vuillemin A; Kalbacher E; Nguyen T; Maurina T; Nallet J; Kim S; Borg C; Kleinclauss F; Pivot X; Adotevi O
    Bull Cancer; 2012 Jul; 99 Suppl 1():S57-65. PubMed ID: 22516539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
    Madan RA; Antonarakis ES; Drake CG; Fong L; Yu EY; McNeel DG; Lin DW; Chang NN; Sheikh NA; Gulley JL
    J Natl Cancer Inst; 2020 Jun; 112(6):562-573. PubMed ID: 32145020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
    Plosker GL
    Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW; Higano CS; Shore ND; Berger ER; Small EJ; Penson DF; Redfern CH; Ferrari AC; Dreicer R; Sims RB; Xu Y; Frohlich MW; Schellhammer PF;
    N Engl J Med; 2010 Jul; 363(5):411-22. PubMed ID: 20818862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
    Higano CS; Schellhammer PF; Small EJ; Burch PA; Nemunaitis J; Yuh L; Provost N; Frohlich MW
    Cancer; 2009 Aug; 115(16):3670-9. PubMed ID: 19536890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sipuleucel-T for the treatment of advanced prostate cancer.
    Frohlich MW
    Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
    Cheever MA; Higano CS
    Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.